Your browser is no longer supported. Please, upgrade your browser.
Index- P/E- EPS (ttm)-0.15 Insider Own6.00% Shs Outstand29.14M Perf Week11.50%
Market Cap183.11M Forward P/E64.33 EPS next Y0.10 Insider Trans0.00% Shs Float12.42M Perf Month47.68%
Income-4.20M PEG- EPS next Q0.04 Inst Own17.10% Short Float0.78% Perf Quarter49.50%
Sales47.00M P/S3.90 EPS this Y537.80% Inst Trans-0.93% Short Ratio0.79 Perf Half Y99.11%
Book/sh1.06 P/B6.31 EPS next Y266.70% ROA- Target Price5.73 Perf Year59.29%
Cash/sh0.90 P/C7.47 EPS next 5Y3.00% ROE-13.30% 52W Range1.46 - 7.00 Perf YTD29.40%
Dividend- P/FCF- EPS past 5Y34.20% ROI4.60% 52W High-4.43% Beta1.89
Dividend %- Quick Ratio1.70 Sales past 5Y10.90% Gross Margin43.10% 52W Low358.22% ATR0.34
Employees216 Current Ratio2.20 Sales Q/Q-8.70% Oper. Margin-3.50% RSI (14)79.29 Volatility7.51% 5.89%
OptionableYes Debt/Eq0.11 EPS Q/Q-230.00% Profit Margin-9.00% Rel Volume1.39 Prev Close6.90
ShortableYes LT Debt/Eq0.05 EarningsNov 18 AMC Payout- Avg Volume122.03K Price6.69
Recom2.00 SMA2024.04% SMA5041.21% SMA20087.74% Volume169,327 Change-3.04%
Apr-15-20Initiated B. Riley FBR Buy $5.50
Jul-28-14Downgrade Northland Capital Outperform → Market Perform $6 → $3.50
Jun-16-14Initiated H.C. Wainwright Buy $6
Mar-05-13Initiated Northland Capital Outperform $6
Nov-18-10Reiterated Morgan Joseph Buy $3 → $5.25
Aug-20-09Reiterated Roth Capital Hold $2.50 → $5
Nov-24-08Reiterated Roth Capital Hold $2.50
Mar-26-08Reiterated Roth Capital Hold $6 → $4.50
Nov-09-07Reiterated Roth Capital Hold $7 → $6
Mar-16-07Reiterated Roth Capital Hold $8.50 → $7
Jan-24-07Reiterated Roth Capital Hold $6.50 → $8.50
Jan-14-21 08:00AM  
Jan-11-21 08:32AM  
Jan-06-21 08:00AM  
Jan-05-21 08:00AM  
Dec-30-20 08:00AM  
Dec-09-20 08:00AM  
Nov-27-20 10:08AM  
Nov-19-20 06:45AM  
Nov-18-20 05:00PM  
Nov-17-20 10:12AM  
Nov-10-20 08:46AM  
Nov-09-20 08:50AM  
Sep-29-20 08:33AM  
Sep-15-20 08:00AM  
Sep-10-20 07:22AM  
Sep-09-20 08:00AM  
Sep-03-20 08:00AM  
Aug-26-20 04:35PM  
Aug-25-20 08:00AM  
Aug-19-20 08:00AM  
Aug-18-20 08:00AM  
Aug-03-20 12:17PM  
Jul-20-20 09:19AM  
Jul-15-20 08:06AM  
Jul-07-20 11:02PM  
Jun-30-20 04:41PM  
May-28-20 08:35AM  
May-27-20 01:36PM  
May-13-20 04:35PM  
May-12-20 04:35PM  
May-06-20 08:30AM  
May-04-20 08:22AM  
Apr-04-20 08:50AM  
Mar-31-20 06:30AM  
Mar-30-20 04:35PM  
Mar-24-20 08:35AM  
Mar-17-20 08:35AM  
Feb-18-20 08:25AM  
Jan-29-20 08:30AM  
Jan-09-20 08:30AM  
Dec-31-19 11:46AM  
Dec-20-19 10:45AM  
Dec-19-19 08:30AM  
Nov-26-19 08:29AM  
Nov-18-19 09:00AM  
Nov-14-19 06:01AM  
Nov-13-19 04:32PM  
Oct-30-19 08:00AM  
Oct-24-19 08:00AM  
Sep-30-19 07:33AM  
Sep-26-19 08:31AM  
Sep-20-19 10:40AM  
Sep-06-19 10:07AM  
Aug-30-19 07:39AM  
Aug-29-19 07:38AM  
Aug-28-19 04:44PM  
Jul-26-19 12:31PM  
Jul-25-19 08:00AM  
Jun-10-19 08:30AM  
May-15-19 04:35PM  
May-14-19 05:14PM  
May-02-19 08:00AM  
Apr-29-19 08:01AM  
Apr-26-19 02:49PM  
Apr-10-19 08:39AM  
Apr-02-19 05:50PM  
Apr-01-19 04:35PM  
Mar-21-19 04:35PM  
Mar-04-19 08:01AM  
Feb-05-19 08:00AM  
Jan-22-19 11:59AM  
Jan-18-19 08:01AM  
Jan-14-19 08:00AM  
Jan-03-19 08:00AM  
Nov-29-18 04:46PM  
Nov-23-18 07:45AM  
Nov-20-18 10:21AM  
Nov-14-18 04:46PM  
Nov-06-18 08:00AM  
Oct-25-18 03:45AM  
Oct-19-18 02:58PM  
Oct-15-18 07:00AM  
Sep-27-18 05:16AM  
Sep-26-18 04:04AM  
Sep-20-18 09:01AM  
Aug-30-18 06:30AM  
Aug-29-18 04:36PM  
Jul-24-18 07:45AM  
Jun-14-18 07:15AM  
Jun-11-18 08:05AM  
EDAP TMS S.A., together with its subsidiaries, develops, produces, markets, distributes, and maintains a portfolio of minimally-invasive medical devices for the treatment of urological diseases worldwide. It operates in two divisions, High Intensity Focused Ultrasound (HIFU) and Urological Devices and Services (UDS). The HIFU division develops, manufactures, and markets medical devices based on HIFU technology for the minimally invasive treatment of urological and other clinical indications. This segment offers Ablatherm, an ultrasound guided robotic HIFU device for the treatment of organ-confined prostate cancer; Ablatherm Fusion that incorporates the company's proprietary fusion software, which merges MRI and ultrasound images; and the Focal One, a HIFU robotic device dedicated to the focal therapy of prostate cancer. It also provides disposables, and leasing and treatment related services; and maintenance services. The UDS division develops, markets, manufactures, and services medical devices for the minimally invasive diagnosis or treatment of urological disorders primarily urinary stones and other clinical indications. This segment offers Sonolith i-move, an extracorporeal shockwave lithotripter to small and mid-size hospitals; and Endo-UP platform, manages urinary stones, as well as Sonolith i-sys. It also leases lithotripters; sells disposables and spare parts; maintenance services; and distributes urodynamic products and urology lasers. The company markets and sells its products through its direct marketing, sales organization, and service platform, as well as through third-party distributors and agents. Its customers include public and private hospitals, urology clinics, and research institutions. The company was founded in 1979 and is headquartered in Lyon, France.